Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients: Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Huh, K. | - |
dc.contributor.author | Lee, S.-O. | - |
dc.contributor.author | Kim, J. | - |
dc.contributor.author | Lee, S.J. | - |
dc.contributor.author | Choe, P.G. | - |
dc.contributor.author | Kang, J.-M. | - |
dc.contributor.author | Yang, J. | - |
dc.contributor.author | Sung, H. | - |
dc.contributor.author | Kim, S.-H. | - |
dc.contributor.author | Moon, C. | - |
dc.contributor.author | Seok, H. | - |
dc.contributor.author | Shi, H.J. | - |
dc.contributor.author | Wi, Y.M. | - |
dc.contributor.author | Jeong, S.J. | - |
dc.contributor.author | Park, W.B. | - |
dc.contributor.author | Kim, Y.J. | - |
dc.contributor.author | Kim, J. | - |
dc.contributor.author | Ahn, H.J. | - |
dc.contributor.author | Kim, N.J. | - |
dc.contributor.author | Peck, K.R. | - |
dc.contributor.author | Kim, M.S. | - |
dc.contributor.author | Kim, S.I. | - |
dc.date.accessioned | 2024-05-04T12:30:34Z | - |
dc.date.available | 2024-05-04T12:30:34Z | - |
dc.date.issued | 2024-03 | - |
dc.identifier.issn | 2093-2340 | - |
dc.identifier.issn | 2092-6448 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/91101 | - |
dc.description.abstract | Cytomegalovirus (CMV) is the most important opportunistic viral pathogen in solid organ transplant (SOT) recipients. The Korean guideline for the prevention of CMV infection in SOT recipients was developed jointly by the Korean Society for Infectious Diseases and the Korean Society of Transplantation. CMV serostatus of both donors and recipients should be screened before transplantation to best assess the risk of CMV infection after SOT. Seronegative recipients receiving organs from seropositive donors face the highest risk, followed by seropositive recipients. Either antiviral prophylaxis or preemptive therapy can be used to prevent CMV infection. While both strategies have been demonstrated to prevent CMV infection post-transplant, each has its own advantages and disadvantages. CMV serostatus, transplant organ, other risk factors, and practical issues should be considered for the selection of preventive measures. There is no universal viral load threshold to guide treatment in preemptive therapy. Each institution should define and validate its own threshold. Valganciclovir is the favored agent for both prophylaxis and preemptive therapy. The evaluation of CMV-specific cell-mediated immunity and the monitoring of viral load kinetics are gaining interest, but there was insufficient evidence to issue recommendations. Specific considerations on pediatric transplant recipients are included. Copyright © 2024 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS. | - |
dc.format.extent | 21 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, Korean Society for AIDS | - |
dc.title | Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients: Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation | - |
dc.type | Article | - |
dc.identifier.wosid | 001244463500016 | - |
dc.identifier.doi | 10.3947/ic.2024.0016 | - |
dc.identifier.bibliographicCitation | Infection and Chemotherapy, v.56, no.1, pp 101 - 121 | - |
dc.identifier.kciid | ART003068402 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85191392493 | - |
dc.citation.endPage | 121 | - |
dc.citation.startPage | 101 | - |
dc.citation.title | Infection and Chemotherapy | - |
dc.citation.volume | 56 | - |
dc.citation.number | 1 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Cytomegalovirus | - |
dc.subject.keywordAuthor | Organ transplantation | - |
dc.subject.keywordAuthor | Prevention | - |
dc.subject.keywordPlus | EXTENDED VALGANCICLOVIR PROPHYLAXIS | - |
dc.subject.keywordPlus | INTERNATIONAL CONSENSUS GUIDELINES | - |
dc.subject.keywordPlus | PREEMPTIVE GANCICLOVIR THERAPY | - |
dc.subject.keywordPlus | GLOBULIN PLUS GANCICLOVIR | - |
dc.subject.keywordPlus | CMV-HYPERIMMUNE GLOBULIN | - |
dc.subject.keywordPlus | HIGH-DOSE VALGANCICLOVIR | - |
dc.subject.keywordPlus | VS. ORAL GANCICLOVIR | - |
dc.subject.keywordPlus | LONG-TERM OUTCOMES | - |
dc.subject.keywordPlus | VALACYCLOVIR PROPHYLAXIS | - |
dc.subject.keywordPlus | IMMUNE GLOBULIN | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.